Literature DB >> 24694892

Influence of platelet-activating factor, lyso-platelet-activating factor and edelfosine on Langmuir monolayers imitating plasma membranes of cell lines differing in susceptibility to anti-cancer treatment: the effect of plasmalogen level.

Michał Flasiński1, Katarzyna Hąc-Wydro, Paweł Wydro, Patrycja Dynarowicz-Łątka.   

Abstract

Three structurally related but differing in biological activities single-chained ether phospholipids (PAF (platelet-activating factor) and lyso-PAF) and an anti-cancer drug (edelfosine (ED)) were investigated in Langmuir monolayers imitating natural membranes. The aim of the undertaken experiments was to study the influence of these lipids on monolayers mimicking plasma membranes of cell lines differing in susceptibility to the anti-cancer activity of ED, i.e. promyelocytic leukaemia cells (HL-60) and promyeloblastic leukaemia cells (K-562). As these cells differ essentially in the cholesterol/phospholipid ratio and plasmalogen concentration in the membrane, we have carried out systematic investigations in artificial systems of various compositions. The results for model leukaemia cell membrane were compared with data acquired for systems imitating normal leucocytes. Our results show that the level of plasmalogens significantly modulates the influence of the single-chained phospholipids on the investigated systems. The experiments confirmed also that the interactions of ether lipids with a model membrane of HL-60 cells (in biological tests sensitive to ED) have opposite character when compared with K-562, being resistant to ED. Moreover, the values of the parameters characterizing monolayers serving as membrane models (strength of interactions, monolayers fluidity and morphology) proved both sensitivity of these cells to ED and lack of their susceptibility towards PAF. Interestingly, it has been found that lyso-PAF, which is usually described as an inactive precursor of PAF, displays a stronger effect on HL-60 model membranes than ED.

Entities:  

Keywords:  Brewster angle microscopy; Langmuir monolayers; plasmalogens; single-chained ether lipids

Mesh:

Substances:

Year:  2014        PMID: 24694892      PMCID: PMC4006236          DOI: 10.1098/rsif.2013.1103

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  38 in total

1.  Platelet-activating factor and human thyroid cancer.

Authors:  Yves Denizot; Thierry Chianéa; François Labrousse; Véronique Truffinet; Manuela Delage; Muriel Mathonnet
Journal:  Eur J Endocrinol       Date:  2005-07       Impact factor: 6.664

2.  Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice.

Authors:  Ander Estella-Hermoso de Mendoza; Miguel A Campanero; Janis de la Iglesia-Vicente; Consuelo Gajate; Faustino Mollinedo; María J Blanco-Prieto
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

3.  The antitumor ether lipid edelfosine (ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: by blocking ERK1/2 and p38 mitogen-activated protein kinases as potential targets.

Authors:  Hye-Kyung Na; Young-Joon Surh
Journal:  Asia Pac J Clin Nutr       Date:  2008       Impact factor: 1.662

4.  Caveolae facilitate but are not essential for platelet-activating factor-mediated calcium mobilization and extracellular signal-regulated kinase activation.

Authors:  Caroline Poisson; Simon Rollin; Steeve Véronneau; Simon M Bousquet; Jean-François Larrivée; Christian Le Gouill; Guylain Boulay; Jana Stankova; Marek Rola-Pleszczynski
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

Review 5.  Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor.

Authors:  Vladislava Melnikova; Menashe Bar-Eli
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  Opposing effects of platelet-activating factor and lyso-platelet-activating factor on neutrophil and platelet activation.

Authors:  Emily J Welch; Ram P Naikawadi; Zhenyu Li; Phoebe Lin; Satoshi Ishii; Takao Shimizu; Chinnaswamy Tiruppathi; Xiaoping Du; Papasani V Subbaiah; Richard D Ye
Journal:  Mol Pharmacol       Date:  2008-10-17       Impact factor: 4.436

Review 7.  Phospholipase A2 structure/function, mechanism, and signaling.

Authors:  John E Burke; Edward A Dennis
Journal:  J Lipid Res       Date:  2008-11-14       Impact factor: 5.922

8.  Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF).

Authors:  M A N D Ferreira; L S Barcelos; M M Teixeira; Y S Bakhle; S P Andrade
Journal:  Life Sci       Date:  2007-05-21       Impact factor: 5.037

9.  Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.

Authors:  B A Wagner; G R Buettner; L W Oberley; C P Burns
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701

10.  Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells.

Authors:  Yuchao Gu; Junhua Zhang; Wenyi Mi; Jing Yang; Feng Han; Xinzhi Lu; Wengong Yu
Journal:  Breast Cancer Res       Date:  2008-01-03       Impact factor: 6.466

View more
  1 in total

Review 1.  Plasmalogen lipids: functional mechanism and their involvement in gastrointestinal cancer.

Authors:  Márcia Cristina Fernandes Messias; Giovana Colozza Mecatti; Denise Gonçalves Priolli; Patrícia de Oliveira Carvalho
Journal:  Lipids Health Dis       Date:  2018-03-07       Impact factor: 3.876

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.